Day: September 27, 2024

– Financing strengthens balance sheet and is expected to provide sufficient cash runway through June 2026 –       – Retiring $17.5 million in Avenue Capital debt, aided by $11.5 million in new debt from insider-led group; eliminates $12 million in scheduled debt payments through June 2026 – – Avenue Capital, current insiders, and select group of healthcare-focused investment funds participated in the equity offering – GARDEN CITY, N.Y., Sept. 27, 2024 (GLOBE NEWSWIRE) —  Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors,...

OSLO, Norway (27 September 2024) – TGS ASA, a leading provider of energy data and intelligence is assigned Ba3 rating with a stable outlook from Moody’s. The USD 450 million backed senior secured notes (originally issued by Petroleum Geo-Services AS, a fully owned subsidiary of TGS) are upgraded two notches from B2 to Ba3 with a stable outlook. Moody’s press release announcing the rating action is available on their home page https://www.moodys.com/. For more information, visit TGS.com or contact: Bård StenbergIR & Communication Mobile: +47 992 45 235investor@tgs.com About TGSTGS provides advanced data and intelligence to companies active in the energy sector. With leading-edge technology and solutions spanning the entire energy value chain, TGS offers a comprehensive range of insights to help clients make better decisions. Our...

GARDEN CITY, N.Y., Sept. 27, 2024 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, is proud to announce the deployment of its groundbreaking LungFit® PH system to the U.S. Naval Hospital Guam. This partnership, made possible through collaboration with TrillaMed, marks a significant advancement in the neonatal critical care unit, offering enhanced care for newborns in need of respiratory support. The LungFit® PH system is an innovative device designed to generate Nitric Oxide (NO) from room air and deliver NO for the treatment of persistent pulmonary hypertension in neonates (PPHN), a condition that affects the lungs and heart of newborns. The system...

– Retiring $17.5 million in Avenue Capital debt and entering into a $11.5 million loan agreement with an insider-led investor group – – Eliminating $12 million in scheduled debt payments through June 2026 – – $11.5 million loan agreement defers payment of principal and interest through June 2026 – – 60% increase in the number of hospital contracts since July 1, 2024, including U.S. Naval Hospital Guam – GARDEN CITY, N.Y., Sept. 27, 2024 (GLOBE NEWSWIRE) — Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients, today announced that it has terminated the loan and security agreements with Avenue Capital and entered into an $11.5 million loan agreement...

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved lung function and also improved health-related quality of life COPD is the most prevalent chronic respiratory disease in China, and is a priority within the government’s Healthy China 2030 public health plan Dupixent is now approved in four indications across respiratory and dermatological diseases in China TARRYTOWN, N.Y. and PARIS, Sept. 27, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the National Medical Products Administration (NMPA) in China has approved Dupixent® (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary...

NEW YORK, Sept. 27, 2024 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced G Mining Ventures Corp. (TSX: GMIN; OTCQX: GMINF), a precious metals mining company, has qualified to trade on the OTCQX® Best Market. G Mining Ventures Corp. upgraded to OTCQX from the Pink® market. On April 22, 2024, G Mining TZ Corp. (formerly G Mining Ventures Corp.) (“Former GMIN”), Reunion Gold Corporation (“Reunion Gold”) and Greenheart Gold Inc. (“Greenheart”, and collectively with GMIN and Reunion Gold, the “Parties”), entered into an arrangement agreement under which the Parties agreed to complete a plan of arrangement under Section 192 of the Canada Business Corporations Act (the “Arrangement”). Pursuant to the Arrangement, which closed on...

WATERTOWN, Mass., Sept. 27, 2024 (GLOBE NEWSWIRE) — Lyra Therapeutics, Inc. (Nasdaq: LYRA), (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting anti-inflammatory therapies for the localized treatment of chronic rhinosinusitis (CRS), today announced that the Company will present results from the Phase 3 ENLIGHTEN 1 study for LYR-210, the company’s lead product candidate for CRS, at the 70th Annual Meeting of the American Rhinologic Society (ARS), taking place September 27-28 in Miami. The Company will also present additional results from the Phase 2 BEACON study for LYR-220 in adult patients with CRS who have had prior ethmoid sinus surgery at the Annual Meeting of the American Academy of Otolaryngology–Head and Neck Surgery (AAO-HNS), taking place September 28 – October 1 in Miami. A poster...

CALGARY, Alberta, Sept. 27, 2024 (GLOBE NEWSWIRE) — Canadian Premium Sand Inc. (“CPS” or the “Company”) (TSXV: CPS) announces that Chief Financial Officer, Cameron Deller will be leaving the Company to accept a new opportunity. CPS is pleased to announce the appointment of Isha Kular as Chief Financial Officer for the Company effective October 3, 2024. Ms. Kular returns to CPS from her previous role as Corporate Controller between 2019 and 2020. Cameron Deller, CFA, has held the position of CFO of the Company since August 2021 and has made significant contributions to the development of the Company’s strategies and financing efforts. He has been a valuable member of the CPS management team. Isha Kular, CPA, CA, MPAcc, is an accomplished financial executive with over 17 years experience bringing a wealth of experience to CPS spanning...

New patent expected to provide market exclusivity into 2036 Zembrace® SymTouch® (sumatriptan succinate injection) 10mg is indicated for the acute treatment of migraine in adults CHATHAM, N.J., Sept. 27, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that the United States Patent and Trademark Office issued U.S. Patent No. 12,097,183 to the Company on September 24, 2024. The patent, entitled “Pharmaceutical Composition for Treating Migraine”, claims use of a pre-filled autoinjector comprising a composition of Zembrace® SymTouch® for treating migraines via subcutaneous administration. This patent, excluding possible patent term extensions, is expected to...